Robuta

https://www.alnylam.com/about-alnylam About Alnylam Discover how Alnylam is using Nobel Prize-winning science to lead the translation of RNA interference (RNAi) into a new, innovative class of medicines. alnylam https://www.rnaiscience.com/alnylam-rnai Alnylam & RNAi Science Education - Medical Information for HCPs | Alnylam RNAi Science - US science educationmedical informationalnylamrnaihcps https://www.mondaq.com/unitedstates/patent/1662904/final-judgment-of-non-infringement-entered-in-alnylam-v-pfizer-vaccine-patent-dispute Final Judgment Of Non-Infringement Entered In Alnylam V. Pfizer Vaccine Patent Dispute - Patent -... Aug 14, 2025 - On July 30, 2025, the U.S. District Court for the District of Delaware entered a Final Judgment in the dispute between Alnylam Pharmaceuticals, Inc. ( pfizer vaccinepatent disputefinaljudgmentnon https://investors.alnylam.com/press-releases Press Releases | Alnylam Pharmaceuticals, Inc. Read our most recent press releases and search through our archive of releases. alnylam pharmaceuticals incpress releases https://www.alnylam.it/ Home | Alnylam Italy alnylamitaly https://alnylampolicies.com/it-ch/privacy Privacy Policy - Italian, Switzerland | Alnylam Policies privacy policy italianalnylam policiesswitzerland https://investors.alnylam.com/financial-information Financial Information | Alnylam Pharmaceuticals, Inc. See reports, filings, and documents that include details of our financial performance. alnylam pharmaceuticals incfinancial information https://investors.alnylam.com/events Events and Presentations | Alnylam Pharmaceuticals, Inc. Find our upcoming events and listen to webcasts from past events. alnylam pharmaceuticals inceventspresentations https://www.alnylam.com/patients/genetic-testing-and-counseling-program Genetic Testing & Counseling for Patients | Alnylam Alnylam Act® provides a no-charge, third-party genetic testing and counseling program. Learn more about speaking to your doctor about eligibility. genetic testingcounselingpatientsalnylam https://alnylampolicies.com/sv/legal Legal Notice - Swedish | Alnylam Policies legal noticealnylam policiesswedish https://investors.alnylam.com/ Information and Resources for Investors | Alnylam The Investor Relations website contains information about Alnylam Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial... informationresourcesinvestorsalnylam https://www.alnylam.com/our-science/alnylam-scientific-advisory-board Scientific Advisory Board | Alnylam Find information about the scientific advisors and founders of Alnylam who are among the world leaders in scientific research. scientific advisory boardalnylam https://www.alnylam.com/about-alnylam/alnylam-challengers Alnylam Challengers | Alnylam Explore the stories of the Alnylam Challengers. Learn about the passionate individuals behind our transformative medicines and their relentless commitment to... alnylamchallengers https://www.alnylam.com/about-alnylam/investigator-initiated-studies Investigator-Initiated Studies (IIS) | Alnylam Find out how to submit a proposal to Alnylam® for an Investigator-Initiated Study—research areas include transthyretin-mediated amyloidosis (ATTR), acute... investigator initiatedstudiesiisalnylam https://www.alnylam.com/medical-professional-resources/early-access-program/givosiran Access denied | Alnylam access deniedalnylam https://investors.alnylam.com/ownership-profile Ownership Profile | Alnylam Pharmaceuticals, Inc. View a detailed shareholder breakdown for Alnylam Pharmaceuticals. alnylam pharmaceuticals incownershipprofile https://www.alnylam.jp/about-alnylam/leadership 岡⽥ 裕 代表取締役社⻑からのメッセージ | Alnylam Japan alnylamjapan https://www.alnylam.com/our-science/making-our-medicines Making our Medicines | Alnylam Precise chemistry, innovative delivery methods, advanced analytics, and cutting-edge manufacturing allow Alnylam to pioneer the RNAi revolution™ makingmedicinesalnylam https://investors.alnylam.com/press-release?id=27761 Alnylam Pharmaceuticals Press Release | Oct 25, 2023 | Alnylam Reports Additional Positive Interim... Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy pharmaceuticals press releaseoct 252023 reportsalnylamadditional https://www.alnylam.com/patients/amyloidosis Information about ATTR Amyloidosis | Alnylam Learn about the causes and symptoms of ATTR amyloidosis, a rapidly progressive, debilitating disease caused by misfolded transthyretin (TTR) protein. attr amyloidosisinformationalnylam https://www.rnaiscience.com/ Alnylam Medical Information for US Healthcare Professionals | Alnylam RNAi Science - US medical informationus healthcarealnylamprofessionalsrnai https://www.alnylam.com/about-alnylam/patient-access-philosophy Patient Access Philosophy | Alnylam Alnylam has remained focused on keeping patients at the center of everything we do, throughout our 20+ year journey in developing RNAi therapeutics. patient accessphilosophyalnylam https://www.alnylam.com/about-alnylam/corporate-responsibility Corporate Responsibility | Alnylam Alnylam's approach to corporate responsibility is to embrace the opportunity to influence and create positive change for patients, our employees and the... corporate responsibilityalnylam https://investors.alnylam.com/investor-toolkit Investor Toolkit | Alnylam Pharmaceuticals, Inc. Find our most recent financial information, including filings, releases, reports, and more. alnylam pharmaceuticals incinvestor toolkit https://www.alnylam.jp/ Alnylam® Pharmaceuticals | Alnylam Japan pharmaceuticalsalnylamjapan https://investors.alnylam.com/press-release?id=22946 Alnylam Pharmaceuticals Press Release | Aug 10, 2018 | Alnylam Announces First-Ever FDA Approval of... Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO™ (patisiran) for the Treatment of the Polyneuropathy of Hereditary... pharmaceuticals press releaseannounces first everaug 10fda approvalalnylam https://www.alnylam.de/ Alnylam® Pharmaceuticals | Deutschland | Alnylam-de pharmaceuticalsdeutschlandalnylam https://alnylam.co.uk/contact-us Contact Us | Alnylam UK How to contact Alnylam Pharmaceuticals UK, location and phone number. usalnylamuk https://www.greatplacetowork.com/certified-company/1324817 Working at Alnylam Pharmaceuticals | Great Place To Work® Is Alnylam Pharmaceuticals a great place to work for? alnylam pharmaceuticalsgreat placeworking https://www.alnylam.com/medical-professional-resources/genetic-testing-counseling Alnylam Act® Genetic Testing | Alnylam Learn about the Alnylam Act® program offering genetic testing and counseling for suspected genetic conditions. Find more information about our no-charge,... genetic testingalnylam https://www.alnylam.com/alnylam-rnai-pipeline Product Development Pipeline | Alnylam Alnylam’s pipeline of investigation RNAi therapeutics is focused on TTR Amyloidosis, cardiovascular, metabolic, neuroscience, hematology, rare and other... product developmentpipelinealnylam https://tradingeconomics.com/alny:us:sales Alnylam Pharmaceuticals | ALNY - Sales Revenues Alnylam Pharmaceuticals reported $1.17B in Sales Revenues for its fiscal quarter ending in March of 2026.Data for Alnylam Pharmaceuticals | ALNY - Sales... alnylam pharmaceuticalssales revenues https://www.alnylam.com/alnylam-rnai-pipeline/clinical-trials About Clinical Trials | Alnylam Learn about what clinical trials are, how they work and Alnylam’s approach to clinical trials. clinical trialsalnylam https://www.alnylam.com/careers Careers | Alnylam At Alnylam we're 'change the world' kind of people. Explore career opportunities with a team that has pioneered RNAi therapeutics. careersalnylam https://www.pharmavoice.com/news/alnylam-onpattro-fda-rejection-rnai-cardiomyopathy/696365/ Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future | PharmaVoice Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans. alnylamceorejectionpivotsfuture https://www.alnylam.com/medical-professional-resources/early-access-program Early Access Programs | Alnylam Learn more about Alnylam's Early Access Program and how we help patients gain access to investigational medicines through compassionate use. early access programsalnylam https://www.alnylam.com/about-alnylam/diversity-inclusion Diversity & Inclusion | Alnylam diversity inclusionalnylam https://alnylampolicies.com/ Alnylam Policies | Alnylam Policies alnylam policies https://jobs.alnylam.com/careers Careers at Alnylam Pharmaceuticals alnylam pharmaceuticalscareers https://www.alnylam.com/about-alnylam/transparency Transparency | Alnylam At Alnylam, we strongly believe that interactions with Health Care Providers and Healthcare Organizations positively influence the quality of patient treatment... transparencyalnylam